Skip to content
10-K

Annual Report

Nuvectis Pharma, Inc. NVCT

0001104659-26-013044

← back to feed
Filed
Feb 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 6, 2026 26.49M sh
Shares Diluted FY 2025 · Dec 31, 2025 21.81M sh
Shares Diluted FY 2025 · Dec 31, 2024 17.11M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$16.01M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$12.25M
Cash And Equivalents FY 2025 · Dec 31, 2025 $31.63M
Cash And Equivalents FY 2025 · Dec 31, 2024 $18.53M
Stockholders Equity FY 2025 · Dec 31, 2025 $18.41M
Stockholders Equity FY 2025 · Dec 31, 2024 $9.71M
Stockholders Equity FY 2025 · Dec 31, 2023 $12.2M
Current Liabilities FY 2025 · Dec 31, 2025 $13.3M
Current Liabilities FY 2025 · Dec 31, 2024 $8.89M
Total Liabilities FY 2025 · Dec 31, 2025 $13.3M
Total Liabilities FY 2025 · Dec 31, 2024 $8.89M
Current Assets FY 2025 · Dec 31, 2025 $31.71M
Current Assets FY 2025 · Dec 31, 2024 $18.61M
Total Assets FY 2025 · Dec 31, 2025 $31.71M
Total Assets FY 2025 · Dec 31, 2024 $18.61M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.32
Eps Diluted FY 2025 · Dec 31, 2024 −$1.11
Eps Basic FY 2025 · Dec 31, 2025 −$1.32
Eps Basic FY 2025 · Dec 31, 2024 −$1.11
Sga Expense FY 2025 · Dec 31, 2025 $9.42M
Sga Expense FY 2025 · Dec 31, 2024 $6.93M
Rd Expense FY 2025 · Dec 31, 2025 $18.15M
Rd Expense FY 2025 · Dec 31, 2024 $12.92M
Net Income FY 2025 · Dec 31, 2025 −$26.44M
Net Income FY 2025 · Dec 31, 2024 −$19M
Operating Income FY 2025 · Dec 31, 2025 −$27.57M
Operating Income FY 2025 · Dec 31, 2024 −$19.85M